Application of VEGF165 plazmid in treatment of critical lower limb ischemia;Zastosowanie plazmidu VEGF165 w leczeniu krytycznego niedokrwienia kończyn dolnych

Polski Merkuriusz Lekarski

Volumn 20, Issue 120, 2006, Pages 655-659

  Skóra, Jan ^a   Sadakierska Chudy, Anna ^a,b   Pupka, Artur ^a   Biegus, Jan ^d,f   Barć, Piotr ^a   Baczyńska, Dagmara ^b,c,e   Janczak, Dariusz ^a   Zacharska, Sylwia ^a   Ugorski, Maciej ^c,e   Dobosz, Tadeusz ^a,b   Szyber, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c Polish Academy of Sciences   (Poland)

^d Wojskowy Szpital Kliniczny z Poliklinika   (Poland)

^e INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^f 4Th Clinical Military Hospital with Polyclinic

Author keywords

Critical ischemia of lower limbs; Gene therapy; VEGF

Indexed keywords

PLASMID VECTOR; VASCULOTROPIN; VASCULOTROPIN 165;

AMPUTATION; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEALTH STATUS; HISTOLOGY; HUMAN; LEG ISCHEMIA; NONVIRAL GENE THERAPY; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SAFETY; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS BLOOD;

ADULT; AGED; CRITICAL ILLNESS; FEMALE; GENE THERAPY; HUMANS; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746134793     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Baumgartner I., Pieczek A., Manor O. i wsp.: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation, 1998, 97, 1114-1123.
2. Choksy S., Pockley A.G., Wajeh Y.E. i wsp.: VEGF and VEGF receptor expression in human chronic critical limb ischaemia. Eur. J. Vase. Endovasc. Surg., 2004, 28, 660-669.
3. Chomczynski P.: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques, 1993, 15, 532-34, 536-37.
4. Clause M., Gerlach M., Gerlach H. i wsp.: Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cells and monocyte procoagulant activity and promotes monocyte migration. J. Exp. Med., 2004, 172, 1535-1545.
5. Dzau V.J., Gnecchi M., Pachori A.S. i wsp.: Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension, 2005, 46, 7-18.
6. Dormandy J.A.: Therapeutic advances in critical limb ischemia. International Congress and Symposium Series No 195. Dublin, 2 May 1992.
7. Fam N.P., Verma S., Kutryk M. i wsp.: Clinician guide to angiogenesis. Circulation, 2003, 108, 2613-2618.
8. Fuchs S., Satler L.F., Kornowski R. i wsp.: Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. J. Am. Col. Cardiol., 2003, 10, 1721-1724.
9. Golledge J.: Lower-limb arterial disease. Lancet, 1997, 350, 1459-65.
10. Heeschen Ch., Lehmann R., Honold J. i wsp.: Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation, 2004, 109, 1615-1622.
11. Heilmann C.A.U., Attmann T., Thiem A. i wsp.: Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia. Eur. J. Cardiothorac. Surg., 2003, 24, 785-793.
12. Hill J.M., Zalos G., Halcox J.P.J. i wsp.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med., 2003, 348, 593-600.
13. Iwaguro H., Yamaguchi J., Kalka Ch. i wsp.: Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation, 2002, 105, 732-738
14. Kołsut R, Małecki M., Żelazny P. i wsp.: Terapia genowa choroby wieńcowej plazmidem phVEGF165-wyniki wczesne. Kardiol. Pol., 2004, 59, 378-383.
15. Lepantalo M., Malzke S.: Outcome of unreconstructed chronic critical leg ischemia. Eur. J. Endovasc. Surg., 1996, 11, 153-57.
16. Managment of peripheral arteria disease (PAD) TransAtlantic Inter-Society Consensus (TASC). Section C. Eur. J. Vase. Endovasc. Surg., 2000, 19, 47-243.
17. McLaren M., Newton D.J., Khan F. i wsp.: Vascular endothelial growth factor in patients with critical limb ischemia before and after amputation. Int. Angiol., 2002, 21, 165-8.
18. Neil P.P., Subodh V., Michael K. i wsp.: Clinician guide to angiogenesis. Circulation, 2003, 108, 2613-2618.
19. Noritoshi Nagaya N., Kenji Kangawa K., Munetake Kanda M. i wsp.: Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation, 2003,108, 889-895.
20. Ozawa C.R., Banfi A., Glazer N.L. i wsp.: Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest., 2004, 113, 516-527.
21. Rajagopalan S., Mohler E., Lederman RJ. i wsp.: Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am. Heart J., 2003, 145, 1114-1118.
22. Simons M., Bonow R.O., Chronos N.A. i wsp.: Clinical trials in coronary angiogenesis: issues, problems, consensus. An expert panel summary. Circulation, 2000, 102, 73-86.
23. Tateishi-Yuyama E., Matsubara H., Murohara T. i wsp.: Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: pilot study and a randomised controlled trial. Lancet, 2002, 360, 427-35.
24. Urbich C., Dimmeler S.: Endothelial progenitor cells. Circ. Res., 2004, 95, 343-353.
25. Yang Y., Jiang-Yong M., Rana J.S. i wsp.: VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells. J. Appl. Physiol., 2002, 93, 1140-1151.
26. Ylä-Herttuala S., Martin J.F.: Cardiovascular gene therapy. Lancet, 2000, 355, 213-22.